ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

| More on:
A man wakes up happy with a smile on his face and arms outstretched.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc. (ASX: RMD) shares are charging higher on Thursday.

In morning trade, the sleep disorder treatment company's shares are up 8% to $35.84.

This follows the release of another strong quarterly update from the company this morning.

ResMed shares jump on quarterly update

For the three months ended 31 March, ResMed reported an 8% increase in revenue to US$1.3 billion.

This was driven by increased demand for its sleep devices and masks portfolio, as well as solid growth across its Residential Care Software business.

Management revealed that this growth was consistent across the globe. Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9%. Whereas revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 8% in constant currency.

Residential Care Software revenue increased by 10% on a constant currency basis, reflecting continued organic growth in its Residential Care Software portfolio

Another positive was ResMed's gross margin, which increased by 140 basis points to 59.3%. This was mainly due to manufacturing and logistics efficiencies, as well as favourable shifts in product mix, partially offset by unfavourable foreign currency movements.

This ultimately led to the company's income from operations increasing by 14% to US$426.3 million and its non-GAAP net income rising 11% to US$348.5 million.

How does this compare to expectations?

According to a note out of Goldman Sachs, it was expecting ResMed to report total revenue of US$1,292 million (consensus: US$1,289 million) and non-GAAP net income of US$354 million (consensus: US$353 million).

This means it has delivered a result largely in line with expectations today.

Management commentary

ResMed's chair and CEO, Mick Farrell, was rightfully pleased with the quarter. He said:

Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for our best-in-class products and software solutions.

We delivered 9% constant currency revenue growth and 140 bps improvement in non-GAAP gross margin. These results are evidence that sleep health customers recognize our products and software solutions as the gold standard for care. Our continued growth was achieved by the incredible commitment of our team that has created a clear market-leading value proposition in connected digital health.

Farrel spoke positively about the future and highlighted the company's massive total addressable market. He adds:

We remain laser-focused on continuing to address the over 2.3 billion people around the globe with sleep health and breathing health issues and all those who need world-class software for healthcare delivered at home. We will continue to drive increased patient flow as we accelerate education and awareness outreach to physicians, providers, patients, and beyond, ensuring a strong pipeline of people who need access to our products and solutions to improve their lives.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »